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Abstract
Objective: Treatment of colorectal cancer (CRC) remains a clinical challenge, as more than 15% of patients are resistant to 5-
Fluorouracil (5-FU)-based chemotherapeutic regimens, and tumor recurrence rates can be as high as 50–60%. Cancer stem
cells (CSC) are capable of surviving conventional chemotherapies that permits regeneration of original tumors. Therefore,
we investigated the effectiveness of 5-FU and plant polyphenol (curcumin) in context of DNA mismatch repair (MMR) status
and CSC activity in 3D cultures of CRC cells.
Methods: High density 3D cultures of CRC cell lines HCT116, HCT116+ch3 (complemented with chromosome 3) and their
corresponding isogenic 5-FU-chemo-resistant derivative clones (HCT116R, HCT116+ch3R) were treated with 5-FU either
without or with curcumin in time- and dose-dependent assays.
Results: Pre-treatment with curcumin significantly enhanced the effect of 5-FU on HCT116R and HCR116+ch3R cells, in
contrast to 5-FU alone as evidenced by increased disintegration of colonospheres, enhanced apoptosis and by inhibiting
their growth. Curcumin and/or 5-FU strongly affected MMR-deficient CRC cells in high density cultures, however MMR-
proficient CRC cells were more sensitive. These effects of curcumin in enhancing chemosensitivity to 5-FU were further
supported by its ability to effectively suppress CSC pools as evidenced by decreased number of CSC marker positive cells,
highlighting the suitability of this 3D culture model for evaluating CSC marker expression in a close to vivo setting.
Conclusion: Our results illustrate novel and previously unrecognized effects of curcumin in enhancing chemosensitization
to 5-FU-based chemotherapy on DNA MMR-deficient and their chemo-resistant counterparts by targeting the CSC sub-
population. (246 words in abstract).
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Introduction
Colorectal cancer (CRC) is the third most frequent cancer
affecting men and women equally worldwide [1]. Current
therapies for the treatment of colorectal cancer mainly comprise
5-Fluorouracil-based chemotherapies that are used individually or
in combination with oxaliplatin (FOLFOX) or anti-angiogenic
agents, and/or anti-epidermal growth factor agents [2]. Although
colon cancer incidence rates have declined somewhat, current
therapies are associated with significant side effects, high expense
and recurrence rates upwards of 50%, primarily due to the
development of acquired chemoresistance to conventional che-
motherapeutics [3,4]. These limitations highlight the imperative
and urgent need for identifying and developing novel and safe
treatment strategies that can help overcome chemoresistance and
enhance tumor cell response to anti-tumor drugs.
Carcinogenesis is believed to be a multistep process that results
from a stepwise accumulation of genetic alterations in various
genes (e. g. metastasis-associated genes, oncogenes, tumor
suppressor genes) leading to progressive conversion of healthy
cells to tumor cells [5,6]. It is now further recognized, that
epigenetic alterations such as aberrant DNA methylation, histone
modifications, chromosome remodeling and damage to the
mismatch repair (MMR) system, also markedly influence CRC
development, [5,7]. Damage to the MMR system causes genetic
instability as it is important for proof reading DNA synthesis errors
during replication, leading to altered cell phenotypes, enhanced
susceptibility for neoplastic transformation and facilitating devel-
opment of chemo-resistant cells [8,9].
During tumorigenesis and tumor dissemination including colon
cancer, cancer cells require self-renewal capability, similar to that
exhibited by stem cells. It is now widely accepted that cancer
pathogenesis in most tumors, including CRC, is driven by a subset
of tumor cells that exhibit stem cell characteristics similar to
physiologic stem cells, including self-renewal abilities and pluri-
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potency [10,11] and that these cancer stem cells (CSC) have the
potential to invade and form distant metastasis [12,13,14]. In the
colon, these colonic CSC aberrantly differentiate generating a bulk
of tumor cells with the larger fraction composed of more
differentiated cells and a small fraction of stem cells, which
eventually replace the healthy colonic stem cells and the entire
colonic crypt is colonized by cancer stem cells and their progeny
[10]. A set of specific markers have been identified for colonic
CSC, including CD133+, CD 44+, CD166+ and ALDH1+ [15,16].
Relapse of tumors after apparently successful chemotherapy is
believed to be by virtue of chemo-resistant CSCs that evade death
by chemotherapeutic drugs [17]. Therefore, new therapeutic
agents that can successfully target CSCs, is very likely the most
promising therapeutic strategy in meeting this tremendous clinical
challenge.
Emerging literature suggests that many dietary components can
directly or indirectly regulate inflammatory responses in the bowel
by modulating the intestinal barrier function [18]. Furthermore,
several naturally occurring dietary compounds have been shown
as anti-cancer therapeutic agents [19,20,21,22]. Indeed evidence is
emerging that conventional chemotherapy in CRC significantly
benefits through combinational treatments with some of such
naturally occurring dietary polyphenols [5,23,24]. One such
botanical, curcumin (diferuloylmethane), a yellow spice derived
from the rhizomes of curcuma longa, has a long tradition as an anti-
inflammatory agent in the traditional Indian Ayurvedic system of
medicine. In addition, several studies have shown that curcumin
acts as a potent chemo- and radiosensitizer in multiple human
cancers [25,26] and can inhibit cell growth of MMR system
deficient colon cancer cells [27,28]. In a previous study, we
demonstrated that curcumin enhanced the chemosensitivity of 5-
FU in colorectal cancer cell lines by targeting NF-kB, Src and NF-
kB-dependent regulated gene products [5]. Furthermore it has
been shown that targeting colon cancer cells with 5-FU and
oxaliplatin (FOLFOX) in combination with curcumin attenuated
EGF-R, IGF-1R and Akt signaling pathway and markedly
reduced cancer stem cell marker positive cells and caused
disintegration of colonospheres [23,24].
We have recently shown that combined treatment of curcumin
with 5-FU induces more significant cytotoxicity in DNA MMR-
deficient CRC monolayer cultures, compared to each agent
individually [5]. Accordingly, the aim of the present study was to
investigate whether curcumin alone or in combination with 5-FU
could affect DNA MMR-deficient colon cancer cells that are
inherently resistant to 5-FU in modulating colonosphere formation
and CSC activity in 3D cultures.
Materials and Methods
Cell Lines and Cell Culture
Human colon cancer cells (HCT116; MMR-deficient) were
obtained from European Collection of Cell Cultures (Salisbury,
UK). HCT116+ch3, is a MMR-proficient cell line, which was
created in our laboratory by the stable transfection of
chromosome 3 bearing a wild-type copy of the hMLH1 gene,
as described previously [29]. We also generated 5-FU resistant
derivatives of these cell lines, referred to as HCT116R and
HCT116+ch3R respectively, that were created by repetitive
treatment of the parental cell lines to increasing concentrations
of 5-FU over a 10–12 month period. Both the parental and 5-
FU resistant cell lines were used to investigate the efficacy of
individual and combined 5-FU and curcumin treatments. The
cells were maintained in tissue culture flasks in Dulbecco’s
modified Eagle medium (DMEM; 4.5 g/L D-glucose) supple-
mented with 10% FBS and 1% antibiotic/antimycotic in a
humidified incubator at 37uC in an atmosphere of 95% air and
5% CO2. The medium was changed every three days, and cells
were passaged using Trypsin/EDTA.
Antibodies
Monoclonal antibodies to ALDH1 were purchased from Acris
Antibodies GmbH (Herold, Germany). Monoclonal antibodies to
CD133 and CD44 were purchased from Abcam PLC (Cambridge,
UK). Antibodies to b-actin (A5316) were from Santa Cruz
Biotechnology (Santa Cruz, CA). Monoclonal anti-PARP [poly(-
ADP-ribose)polymerase] (7D3-6) antibody was purchased from
Becton Dickinson (Heidelberg, Germany). Alkaline phosphatase
linked sheep anti-mouse and sheep anti-rabbit secondary antibod-
ies for immunoblotting were purchased from Millipore (Schwal-
bach, Germany). All antibodies were used at concentrations and
dilutions recommended by the manufacturer.
Growth Media, Chemicals, and Cytokines
Growth medium (Ham’s F-12/Dulbecco’s modified Eagle’s
medium (50:50) containing 10% fetal bovine serum (FBS), 25 mg/
ml ascorbic acid, 50 IU/ml streptomycin, 50 IU/ml penicillin,
2.5 mg/ml amphotericin B, essential amino acids and L-glutamine)
was obtained from Seromed (Munich, Germany). Trypsin/EDTA
(EC 3.4.21.4) was purchased from Biochrom (Berlin, Germany).
Epon was obtained from Plano (Marburg, Germany). 5-FU was
purchased from Sigma (Munich, Germany). Curcumin (BCM-95)
was a generous gift from Dolcas Biotech (Landing, NJ, USA).
Curcumin was prepared by dissolving it in dimethylsulfoxide
(DMSO) at a stock concentration of 5000 mM and stored at
220uC. Serial dilutions were prepared in culture medium.
A 100 mM stock of 5-FU was prepared in absolute DMSO and
stored at 220uC. The concentration of DMSO was less than 1%
of drug treatment. For treatment, 5-FU was diluted in DMEM and
added to cultures to give the desired final concentration. After 70–
80% confluency, the cells were treated with 5-FU or curcumin
individually, or their combination.
Cell Viability Assay
The cell viability was evaluated by the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) uptake method as
described previously [30]. Briefly, HCT116, HCT116+ch3 cells
and the 5-FU chemo-resistant cell lines were seeded in a 96-well
plate (1000 per well) and exposed to different concentrations of
individual 5-FU or curcumin in triplicate for the indicated time
periods to obtain the IC50 values (50% cell growth inhibitory
concentrations). Additionally, in another set of experiments, cells
were pretreated with 5 mM curcumin for 12 h and then co-treated
with different concentrations of 5-FU (0, 0.1, 1, 2, 3, 4 mM) for
24 h to obtain the optimum dose for combination treatment. Cells
were washed twice with PBS and subsequently, MTT solution
(5 mg/mL) was added to each well and the plate was incubated for
2 h at 37uC. The lysis buffer (20% SDS and 50% dimethyl
formamide) was added, and the cells were incubated overnight at
37uC. The absorbance of the cell suspension was measured at
570 nm (OD570) using Revelation 96-well multiscanner plate
reader (Bio-Rad Laboratories Inc. Munich, Germany). The data
obtained were calculated and were represented as percentage of
survival relative to controls. This experiment was repeated 3 times
independently, and statistical analysis was done to obtain the final
values.
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Formation and Inhibition of Colonosphere Colonies
For tumor colonosphere formation assay, 10 ml drop, approx-
imately 2 million cells, HCT116, HCT116+ch3 and their
respective 5-FU chemo-resistant derivative cell lines were plated
on a cellulose filter on top of a steel mesh bridge [31]. Cell culture
medium reached the filter medium interface and cells were
nurtured through diffusion. This model allows the cells to
aggregate, and form a distinct pellet, which was examined after
1–10 days. The HCT116, HCT116+ch3 and their respective 5-
FU chemo-resistant cell lines were treated with curcumin (20 mM),
5-FU (5 mM) or their combination (curcumin 5 mM and 5-FU
0.1 mM) for 1, 3, 7 and 10 days, respectively. Applied concentra-
tions were calculated and represented as percentage survival with
respect to untreated controls. The IC50 was defined as the drug
concentration required to inhibit HCT116, HCT116R or
HCT116+ch3 and HCT116+ch3R by 50% relative to controls.
IC50 values were estimated from the dose response curve. Data
were derived from at least three independent experiments.
Colonosphere formation was assessed by light microscopy, DAPI
(49,6-Diamidino-2-phenylindole, Sigma) and electron microscopy.
Transmission Electron Microscopy (TEM)
Electron microscopy was performed as previously described
[32]. Briefly, high density cell cultures, treated as described above,
were fixed for 1 h in Karnovsky’s fixative followed by post-fixation
in 1% OsO4 solution. After dehydration in an ascending alcohol
series, cultures were embedded in Epon and cut ultrathin with a
Reichert-Jung Ultracut E (Darmstadt, Germany). Sections were
contrasted with a mixture of 2% uranyl acetate/lead citrate and
examined with a transmission electron microscope (TEM 10,
Zeiss, Institute for pharmacology Berlin, Germany).
Quantification of Mitochondrial Changes (MC) and
Apoptotic Cell Death
Ultrathin sections of the samples were prepared and evaluated
with an electron microscope (TEM 10; Zeiss, Institute for
pharmacology Berlin, Germany). To quantify the MC and
apoptotic cells, the number of cells with morphological features
of apoptotic cell death was determined by scoring 100 cells from
25 different microscopic fields.
DAPI Staining for Apoptotic Cells
Chromatin condensation and apoptotic cells were examined by
nuclear staining with DAPI (49,69-Diamidino-2-phenylindole,
Sigma), as previously described [32]. Briefly, the high density
cultures were immersed in O.C.T. embedding medium and
immediately frozen in liquid nitrogen. Eight to ten mm thick
sections were cut. Sections were fixed with methanol for 30 min at
4uC in the dark. Subsequently, the cultures were washed twice
with PBS, and then 1 ml of DAPI solution (5 mg/ml) in five ml
PBS was spread over the cultures followed by incubation for
20 min in the dark. Labelled cells were washed repeatedly with
PBS to remove the excess DAPI stain, covered with fluoromount
mountant and evaluated under a fluorescence microscope (Leica,
Germany). Experiments and analysis were performed in triplicate.
Western Blot Analysis
To determine the effect of curcumin, 5-FU or curcumin/5-FU
on cleavage of PARP and the expression of cancer stem cell (CSC)
markers, whole cell lysates were prepared and fractioned by SDS-
PAGE [33]. Briefly, cells were rinsed in PBS, and the proteins
were extracted with lysis buffer (50 mM Tris/HCl (pH 7.2),
150 mM NaCl, 1% (v/v) Triton X-100, 1 mM sodium orthova-
nadate, 50 mM sodium pyrophosphate, 100 mM sodium fluoride,
0.01% (v/v) aprotinin, pepstatin A (4 mg/ml), leupeptin (10 mg/
ml), and 1 mM phenylmethylsulfonyl fluoride (PMSF)) for 30 min
on ice. After adjusting the total protein concentration, equal
quantities (500 mg protein per lane) of total proteins were
separated by SDS-PAGE (7.5% or 12% gels) under reducing
conditions. Separated proteins were transferred to nitrocellulose
membranes and incubated in blocking buffer (5% (w/v) skimmed
milk powder in PBS, 0.1% Tween 20) for 1 h at room
temperature. Membranes were incubated overnight with the
primary antibody diluted in blocking buffer at 4uC on a shaker,
washed 3 times with blocking buffer, and then incubated with the
secondary antibody conjugated with alkaline phosphatase for
90 min at room temperature. Membranes were washed 3 times in
0.1 M Tris (pH 9.5) containing 0.05 M MgCl2 and 0.1 M NaCl.
Finally, specific antigen-antibody complexes were detected using
nitroblue tetrazolium and 5-bromo-4-chloro-3-indoylphosphate (p-
toluidine salt; Pierce, Rockford, IL, USA) as substrates for alkaline
phosphatase.
Statistical Analysis
Numerical data are expressed as the mean values (+/2SD) for a
representative experiment performed in triplicate. The means
were compared using Student’s t test assuming equal variances.
Differences were considered to be statistically significant if the p
value was less than 0.05.
Results
Human MMR-deficient and -proficient CRC cells (HCT116,
HCT116+ch3) and their respective 5-FU chemo-resistant deriv-
ative cell lines (HCT116R, HCT116+ch3R) were used in our
study to investigate the effect of curcumin or/and 5-FU on cell
viability, apoptosis and cancer stem cells (CSC) in high density
cultures.
MMR- Deficient CRC Cells and Their Respective 5-FU
Resistant Cells are Sensitive to Curcumin
The cytotoxic effects of 5-FU or curcumin on four colon cancer
cell lines were determined using the MTT assay. The cells were
treated with different concentrations of 5-FU (0, 1, 5, 10 and
20 mM) or curcumin (0, 1, 5, 10 and 20 mM) and cell viability was
examined by MTT assay (Fig. 1A & 1B). We observed that 5-FU
blocked the proliferation of the cell lines HCT116, HCT116+ch3
in a dose-dependent manner with an IC50 value of 5 mM, whereas,
their respective 5-FU resistant derivatives did not have any
response to 5-FU treatment (Fig. 1A). The HCT116+ch3 cells and
the corresponding 5-FU chemo-resistant cell lines were equally
sensitive to curcumin (IC50 5 mM), whereas the DNA MMR-
deficient cell lines HCT116 and HCT116R cells were less sensitive
to curcumin compared to the DNA MMR-proficient cell lines
HCT116+ch3 and HCT116+ch3R (IC50 20 mM; Fig. 1B). These
results suggest that the restoration of hMLH1 activity in the
HCT116 cell line, by introduction of chromosome 3, was
associated with an increased sensitivity to 5-FU.
To evaluate cell sensitivity to the combination of curcumin and
5-FU treatment, we pretreated HCT116, HCT116+ch3 and the
respective 5-FU chemo-resistant cells first with 5 mM curcumin
followed by treatment with different concentrations of 5-FU (0,
0.1, 1, 2 and 4 mM) for 24 h (Fig. 1C). MTT assays were
performed and IC50 values were determined. The results show
that curcumin significantly enhanced the cytotoxicity of 5-FU for
both cell lines (HCT116 and HCT116+ch3) at approximately
0.1 mM 5-FU (Fig. 1C). Interestingly, pretreatment with 5 mM
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curcumin reduced IC50 values for 5-FU to 2 mM in the 5-FU
resistant HCT116R and HCT116+ch3R cells lines (p,0.05;
Fig. 1C). These results suggest that DNA MMR-deficient
HCT116R and DNA MMR-proficient HCT116+ch3R cells
pretreated with curcumin were more sensitive to 5-FU than cells
treated with 5-FU alone and the introduction of chromosome 3 in
HCT116 cells showed an increased sensitivity of the cells to the
treatment with 5-FU and/or curcumin compared to the HCT116
cells.
Curcumin and/or 5-FU Suppress Colonosphere Growth of
MMR-deficient CRC Cells and Their Respective 5-FU
Resistant Cells in High Density Cultures
To evaluate the effects of 5-FU and/or curcumin either alone or
in combination on the size of colonospheres, a prominent feature
of cancer stem cells [34], three-dimensional high-density cultures
[31] of the HCT116 and the corresponding chemo-resistant cell
lines were performed (Fig. 2A–C).
In untreated control cultures, the results showed that both
HCT116 and HCT116R cells formed spheroid colonies, with a
time-dependent increase in the size of colonospheres during the 10
day period (Fig. 2A, 2B). Treatment of HCT116 cultures with 5-
FU alone, in contrast to their corresponding 5-FU resistant
HCT116R cell line, dramatically reduced the size of colono-
spheres compared with the corresponding controls (Fig. 2A, 2B).
As expected, treatment of 5-FU resistant cells with 5-FU
individually did not have a negative effect on colonosphere size
(Fig. 2B). In contrast, in cultures treated with curcumin alone and/
or 5-FU, the colonosphere size was significantly decreased when
compared with the corresponding controls (Fig. 2A, 2B, 2C). The
treatment with curcumin alone or the combination treatment was
shown to be highly effective in inhibiting the sphere forming ability
of all four CRC cell lines. The sizes of colonospheres in with
curcumin treated groups were significantly smaller compared to
the control groups, indicating that a) curcumin by itself supressed
colonosphere size in DNA MMR deficient HCT 116 cells, and b)
Figure 1. Cell viability is reduced by 5-FU, curcumin and the combination treatment in HCT116, HCT116+ch3 and the
corresponding 5-FU resistant cell lines. HCT116, HCT116+ch3, HCT116R and HCT116+ch3R cell lines were treated with different concentrations
of 5-FU (0, 1, 5, 10 and 20 mM) alone (A) for 24 hours, different concentrations of curcumin (0, 1, 5, 10 and 20 mM) alone (B) for 24 hours, or were pre-
treated with curcumin 5 mM for 4 h, and then exposed to different concentrations of 5-FU (0, 0.1, 1, 2, 4) for 24 hours (C). Cell viability was measured
with the MTT method and IC50 determined at 50% growth inhibition. The results are provided as mean values with standard deviations from at least
three independent experiments. Values were compared to the control and statistically significant values with p,0.05. Significant values are marked
with (*).
doi:10.1371/journal.pone.0085397.g001
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curcumin sensitized HCT116R and HCT116+ch3R cells to 5-FU-
induced cytotoxicity (Fig. 2A, 2B, 2C). At the end of the
experimental period (10 days), it could be observed that while
the control cells formed well-developed colonospheres, the 5-FU
Figure 2. Curcumin inhibits colonosphere formation in HCT116, HCT116+ch3 and their respective 5-FU-chemoresistant cell lines by
heightening the chemosensitivity to 5-FU treatment in high density cultures. High density cultures of HCT116 (A) or HCT116R (B) cells were
either left untreated or were treated with 5-FU (5 mM), curcumin (20 mM), or 5-FU/curcumin in combination (0.1/5 mM). Cultures were evaluated after
1, 3, 7, and 10 days, and pictures of the native cultures taken. Pictures are representative of three individual experiments. Colonosphere size was
measured and results presented are mean values with standard deviations from three independent experiments. C: High density cultures of HCT116,
HCT116+ch3 and their respective 5-FU-chemoresistant cells were either left untreated or were treated with 5-FU (5 mM), curcumin (20 mM), or 5-FU/
curcumin in combination (0.1/5 mM). Cultures were evaluated after 10 days, colonosphere size was measured and results presented are mean values
with standard deviations from three independent experiments. Significant values are marked with (*).
doi:10.1371/journal.pone.0085397.g002
Curcumin Chemosensitizes MMR-Deficient CRC Cells
PLOS ONE | www.plosone.org 5 January 2014 | Volume 9 | Issue 1 | e85397
resistant CRC cells exposed to curcumin alone or in combination
treatment showed significantly smaller spheroid formation
(Fig. 2C). Taken together, these results indicate that colonoshere
size was markedly decreased in high density cultures treated either
with curcumin alone or combination of curcumin and 5-FU,
indicating a colonosphere inhibiting effect of curcumin and/or 5-
FUon HCT116, HCT116+ch3 and their respective 5-FU resistant
derivatives.
Curcumin and/or 5-FU Increase Cytotoxicity of
Colonospheres of MMR-deficient CRC Cells and Their
Respective 5-FU Resistant Cells in High Density Cultures
To examine whether the colonosphere formation-inhibitory
effect of curcumin and 5-FU in HCT116, HCT116+ch3,
HCT116R and HCT116+ch3R cell lines is related to the
induction of apoptosis, treated cells were evaluated using DAPI
staining, which showed that apoptotic bodies containing nuclear
fragments and chromatin condensation were generated within the
apoptotic pool of cells (Fig. 3A, 3B). Indeed, incubation of
HCT116 and HCT116R cells in serum-starved medium resulted
in the formation of colonosphere during a period of 10 days.
However, incubation of HCT116 and HCT116R cells with 5-FU,
curcumin, or curcumin together with 5-FU for 10 days resulted in
a marked disintegration of colonosphere(s) when compared with
their corresponding controls (Fig. 3A, 3B). Highest disintegration
was observed in response to the combination of curcumin and 5-
FU in HCT116+ch3 and HCT116+ch3R cell lines (Fig. 3A, 3B).
Curcumin Enhances 5-FU-mediated Apoptosis of MMR-
deficient CRC Cells and Their Respective 5-FU Resistant
Cells in High Density Cultures
To examine whether the growth-inhibitory effect of curcumin
and 5-FU in colonosphere formation in three-dimensional high-
density cultures is related to the induction of apoptosis,
ultrastructural evaluations were performed (Fig. 4 & 5) in
HCT116, HCT116+ch3, HCT116R and HCT116+ch3R cells
treated with 5-FU (5 mM) and curcumin (20 mM) individually, or
5-FU/curcumin in combination (0.1/5 mM) for 1, 3, 7, and 10
days. In control cultures, HCT116, HCT116+ch3 and their 5-FU-
resistant counterpart cell lines exhibited large rounded viable cells
(containing distinct distribution of endoplasmic reticulum, mito-
chondria and other cellular organelles) and these cells made
intimate cell-to-cell contact (Fig. 4A, 5A). Treatment of HCT116
cells with 5-FU or curcumin alone resulted in degeneration of cell
organelles, mitochondrial swelling and appearance of multiple
vacuoles, with prominent signs of apoptosis especially in curcumin-
treated high density cultures around day 10 (Fig. 4A–B). These
included areas of condensed heterochromatin within the nuclei,
and multiple autophagocytic cytoplasmic vacuoles. Similar obser-
vations were made for HCT116+ch3 cells (data not shown). In
contrast, such effects could not be observed in 5-FU or curcumin
treated HCT116R (Fig. 5A–B) or HCT116+ch3R cells (data not
shown). However, a combinatorial treatment of 5-FU and
curcumin over 10 days markedly enhanced degeneration of all
tumor cells. Marked degenerative changes and apoptotic cells were
detected around day 3 in HCT116 (Fig. 4A–B) and HCT116R
cells (Fig. 5A–B), that were already visible around day 1 in
HCT116+ch3 cells (Fig. 4A–B) and HCT116+ch3R cells (Fig. 5A–
B). Quantification and statistical analysis of the ultrastructural data
highlights the prominent effects of combined 5-FU and curcumin
treatment on inducing and enhancing mitochondrial changes
(MC) and apoptotic effects in HCT116 cells (Fig. 4B) and
HCT116R cells (Fig. 5B).
Curcumin Potentiates the Antitumor Effect of 5-FU
through Apoptosis Pathway in HCT116, HCT116+ch3
Cells and Their Respective 5-FU Resistant Cells in High
Density Cultures
Since ultrastructural evaluation with electron microscopy results
showed that 5-FU+/2curcumin-induced apoptosis (Fig. 4–5), and
PARP appears to be involved in the induction of apoptosis in
tumor cells [35], therefore we investigated whether curcumin
potentiates PARP cleavage in with 5-FU-treated HCT116,
HCT116+ch3 and their corresponding 5-FU-resistant counter-
parts. As shown in Fig. 6, immunoblot analysis demonstrated that
the cleavage of PARP was enhanced, when the cells were exposed
to curcumin (20 mM) or 5-FU (5 mM) alone, or in the
combination of curcumin and 5-FU (0.1/5 mM). These effects
were more pronounced in combination treatment with curcumin
and 5-FU than in single treatments (Fig. 6).
Curcumin has Potent Chemosensitization Effect on Colon
Cancer Stem Cells in MMR-Deficient and -proficient CRC
Cells in High Density Cultures
To demonstrate the chemosensitization effect of curcumin on
colon CSC markers CD133, CD44 and ALDH1 expression in
high density cultures, western blotting analysis was performed
(Fig. 7). High density cultures of HCT116, HCT116+ch3 and
their corresponding 5-FU-resistant counterparts were either left
untreated, or were treated with 5-FU (5 mM) or curcumin (20 mM)
alone, or 5-FU/curcumin in combination (0.1/5 mM) for 12 h.
Control HCT116 and HCT116+ch3 high density cultures had
strong colon CSC marker expression (Fig. 7A, B, C). In contrast,
immunoblotting analysis of whole cell lysates showed marked
down regulation of CD133, CD44 and ALDH1 in HCT116,
HCT116+ch3, HCT116R and HCT116+ch3R cells in high
density cultures treated with either 5-FU, curcumin or the
combination of 5-FU and curcumin (Fig. 7A, B, C). The
combination treatment of 5-FU/curcumin, although it contains
only low concentrations of 5-FU compared to 5-FU treatment
alone, proved to be most effective in down regulating colon stem
cell marker expression. Densitometric analysis of typical Western
blot experiments performed in triplicate show down regulation of
CD133, CD44 and ALDH1 in HCT116, HCT116+ch3,
HCT116R and HCT116+ch3R cells in high density cultures
treated with either 5-FU, curcumin or the combination of 5-FU
and curcumin (Fig. 7A, B, C). Taken together, this demonstrates
the strong chemosensitizing effect of curcumin on colon CSC in
both MMR-deficient and –proficient tumor cells in high density
cultures.
Discussion
The major purpose of this study was to investigate the efficacy of
curcumin, a pharmacologically safe natural agent, for its potential
chemopreventive and chemosensitization properties to 5-FU in 5-
FU resistant mismatch repair deficient (MMR-deficient) colorectal
cancer (CRC) cells in a three dimensional high density environ-
ment. We herein report that in high density culture curcumin
alone or in combination with 5-FU significantly blocked prolifer-
ation, formation of colonospheres, induced apoptosis and down
regulated colon cancer stem cell markers in MMR-deficient 5-FU
resistant cells.
It has been reported that 5-FU is routinely used for the
management of patients with CRC [36]. However, the use of 5-
FU as a colorectal cancer chemotherapeutic agent has been
somewhat limited due to the toxicities, limited success and
Curcumin Chemosensitizes MMR-Deficient CRC Cells
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associated adverse side effects. Recent research has suggested that
plant polyphenols, such as curcumin, the major compound of
turmeric and a nontoxic, naturally occurring dietary agent, might
be used to sensitize tumor cells to chemotherapeutic therapy by
suppression of pathways that lead to the development of
chemoresistance in cancer cells [5,23,24,37].
In this report, we observed increased sensitivity of
HCT116+ch3 and their respective 5-FU chemo-resistant deriva-
tive cells to the treatment with 5-FU and/or curcumin compared
to HCT116 and their respective 5-FU chemo-resistant derivative
cells, suggests that these two cell populations respond differentially
to 5-FU. Further, it has been previously reported that deficiencies
in the MMR system increase the rate of genomic mutations and
enhance the susceptibility to tumors including colorectal cancer
[38,39] and that damage to the MMR system through epigenetic
alterations causes genetic instability and facilitates neoplastic
transformation [8,9]. Interestingly, it has been shown that
inactivation of a MMR gene such as hMLH1, which can cause
Figure 3. Cytotoxicity of 5-FU, curcumin and the combination treatment on colon cancer cells in high density cultures. High density
cultures of HCT116, HCT116+ch3 (A), or HCT116R and HCT116+ch3R (B) were either left untreated or were treated with 5-FU (5 mM), curcumin
(20 mM), or 5-FU/curcumin in combination (0.1/5 mM). Cultures were evaluated after 1, 3, 7, and 10 days, and stained with Hoechst 33258 (DAPI) to
reveal apoptotic changes of the cell nuclei. Pictures are representative of three individual experiments.
doi:10.1371/journal.pone.0085397.g003
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microsatellite instability (MSI), in colorectal cancer patients
reduces 5-FU induced apoptosis [40]. Indeed, this observation is
consistent with the reports of Sargent and colleagues that CRC
patients with defective DNA mismatch repair (III stage) do not
benefit from 5-FU treatment [41], suggesting that different
mismatch colon cancer cells could exhibit different chemosensi-
tivity patterns. Moreover, it has been reported that curcumin can
inhibit cell growth of MMR-deficient colon cancer cells [27,28].
Additionally Jiang et al. propose that anti-tumorigenic effect of
curcumin is based on failure of MMR deficient tumor cells to
develop curcumin induced double strand breaks and in the end
this results in triggering apoptosis [42]. Therefore, we purposely
chose the MMR-deficient colon carcinoma cell lines HCT116 and
its counterpart 5-FU resistant derivative clones (HCT116R),
together with an isogenic clone of HCT116 cells bearing a
restored hMLH1 gene through a chromosome 3 transfer
(HCT116+ch3) and its corresponding isogenic 5-FU resistant
derivative clones (HCT116+ch3R). Our results demonstrate that
with curcumin the proliferation of MMR-deficient and proficient
CRC cells as well as their corresponding 5-FU resistant derivatives
Figure 4. Ultrastructural evaluation of cytotoxicity of 5-FU, curcumin and the combinational treatment on HCT116 and
HCT116+ch3 cells in high density cultures. A: High density cultures of HCT116 and HCT116+ch3 were either left untreated or were treated with
5-FU (5 mM), curcumin (20 mM), or 5-FU/curcumin in combination (0.1/5 mM). Cultures were evaluated after 1, 3, 7, and 10 days, and evaluated
ultrastructurally with a transmission electron microscope. At the earliest time point when apoptosis (arrows) was first detected, images are
highlighted in red boxes. Micrographs shown are representative of three individual experiments. Magnification: x5000, bar = 1 mm. B: Mitochondrial
changes (MC) and apoptosis were quantified by counting 100 cells with morphological features of apoptotic cell death from 25 different microscopic
fields and results presented are mean values with standard deviations from three independent experiments. Significant values are marked with (*).
doi:10.1371/journal.pone.0085397.g004
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was suppressed and the effect of 5-FU was potentiated in a dose-
dependent manner, thereby reducing the proliferation of CRC
cells significantly as evidenced by the MTT assays and reduced
colonosphere formation. This is in agreement with previous
reports that curcumin exhibits synergistic activity with 5-FU
against Tumor cells [24,43,44]. Recently we have already shown a
synergistic, pro-apoptotic effect of curcumin and 5-FU in MMR-
deficient and proficient colorectal cancer cells in monolayer
cultures [5]. Novel in the present report, we demonstrate that
curcumin potentiated the antitumor effects of 5-FU in the parental
as well as the 5-FU resistant derivatives of these cells in a three
dimensional high density environment resembling the in vivo
situation. Our presented results underline the tumor inhibiting
effect of curcumin and demonstrate the potential benefit in
chemotherapy through combination of curcumin and 5-FU
through a synergistic action in enhancing tumor cell death also
by influencing the MMR-system.
Figure 5. Ultrastructural evaluation of cytotoxicity of 5-FU, curcumin and the combinational treatment on HCT116 5-FU-
chemoresistant and HCT116+ch3 5-FU-chemoresistant cell lines in high density cultures. A: High density cultures of HCT116R and
HCT116+ch3R were either left untreated or were treated with 5-FU (5 mM), curcumin (20 mM), or 5-FU/curcumin in combination (0.1/5 mM). Cultures
were evaluated after 1, 3, 7, and 10 days, and evaluated ultrastructurally with an electron microscope. At the earliest time point when apoptosis
(arrows) was first detected images are highlighted in red boxes. Micrographs shown are representative of three individual experiments. Magnification:
x5000, bar = 1 mm. B: Mitochondrial changes (MC) and apoptosis were quantified by counting 100 cells with morphological features of apoptotic cell
death from 25 different microscopic fields and results presented are mean values with standard deviations from three independent experiments.
Significant values are marked with (*).
doi:10.1371/journal.pone.0085397.g005
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We further found that 5-FU or curcumin treatment individu-
ally, or in combination (curcumin with 5-FU), significantly
suppresses CSCs as revealed by decreased expression of specific
CSCs markers (CD44, CD133 and ALDH1) and colonosphere
formation in MMR-deficient and proficient tumor cells and their
chemo-resistant counterparts in high density cultures. Only a small
subgroup of the tumor cell population is responsible for tumor
invasion and renewal potential, also referred to as cancer stem cells
(CSCs), which express cell surface markers such as CD44, CD166,
CD133 and ALDH1 [45]. It has been reported that the lack of a
Figure 6. Effect of curcumin on 5-FU-induced apoptotic signaling in HCT116, HCT116+ch3 and their respective 5-FU-
chemoresistant cell lines in high density cultures. High density cultures of HCT116 and HCT116+ch3 (left lanel) and of HCT116R and
HCT116+ch3R (right panel) cells were either left untreated or were treated with 5-FU (5 mM), curcumin (20 mM), or 5-FU/curcumin in combination
(0.1/5 mM). Cultures were evaluated after 3 days and whole cell lysates prepared and analyzed by western blotting for cleavage of PARP. Western
blots shown are representative of three independent experiments. The housekeeping protein b-actin served as a positive loading control in all
experiments.
doi:10.1371/journal.pone.0085397.g006
Figure 7. Colon cancer stem cell marker expression in high density cultures as shown by western blotting evaluation. High density
cultures of HCT116 and HCT116+ch3 (left lanel, A, B, C) and of HCT116R and HCT116+ch3R (right panel, A, B, C) cells were either left untreated or
were treated with 5-FU (5 mM), curcumin (20 mM), or 5-FU/curcumin in combination (0.1/5 mM). Cultures were evaluated after 3 days and whole cell
lysates prepared and analyzed by western blotting and quantitative densitometry for expression of CD133, CD44 and ALDH1. Western blots shown
are representative of three independent experiments. The housekeeping protein b-actin served as a positive loading control in all experiments.
Significant values are marked with (*).
doi:10.1371/journal.pone.0085397.g007
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three-dimensional surrounding in a monolayer culture may reduce
the stem cell surface marker expression in a tumor cell culture
[46], therefore in this study, we have used a high density culture
3D model, as this resembles the extensive cell–cell interactions
observed in vivo. Further, it has been suggested that CSCs develop
resistance to chemotherapeutic drugs and induce remission,
providing basis for why cancer cells cannot be completely
destroyed by conventional chemotherapeutic agents [14]. Inter-
estingly, it has been previously suggested that development of
tumor cell resistance to chemotherapeutic agents is correlated to
an increase in cancer stem cell (CSC) population and enhanced
ability to form colonospheres [24]. These observations may help
explain why it is difficult to completely abolish tumor cells and why
nearly 50% of patients develop tumor recurrence after few years of
their cancer treatment. Several lines of evidence have suggested
that many different tumor cells develop from a small subpopula-
tion of CSCs through their oncogenic transformations [47,48] and
that, in addition, CSCs can develop from healthy and progenitor
cells by transforming gene mutations, since many of them have still
features from origin and surrounding differentiated cells, impli-
cating that these mutations may happen in differentiated tissue
cells [49,50,51].
Therefore, it is quite challenging to investigate agents that can
effectively downregulate CSCs in colon cancer cells, and decrease
the carcinogenic potential of CRC. Indeed, our results are
consistent with studies showing that curcumin together with
FOLFOX (5-FU and oxaliplatin) decreased the expression of
several colon CSC receptors, EGFR and inhibition of colono-
sphere-formation in the FOLFOX-surviving cells [24]. Although,
the molecular mechanisms that support curcumin-induced inhibi-
tion of tumor cell growth is not fully understood, the results of
other investigations and our laboratory have shown that curcumin
blocks the activation of b-catenin as well as NF-kB [5,52,53].
Furthermore, it has been discussed that increasing the expression
of CSCs in FOLFOX-treated CRC cells and development of
chemo-resistant potential could be induced by changes in gene-
hypermethylation and stabilizing chromatin thus blocks binding of
transcription factors to genes, which is downregulated by
curcumin [24,54,55]. Indeed, Hollenbach et al. demonstrated
that loss of MMR provides an in vivo survival advantage to the
stem cell population in the presence of DNA damage that may
have implications for cancerogenesis [56].
In most human cancers with DNA MMR deficiency, there is a
direct correlation between a damaged cell and emergence of
chemotherapy resistant CSCs [57]. It is believed that the
activation of DNA MMR system would help in inhibiting the
survival mechanisms by raising the sensitivity of such cells to
therapeutic drugs and reduce its tumor potential by arresting their
growth. Owning to the mass effect, progeny cancer cells still show
the symptoms in the patients and therefore, the combinational
therapy using curcumin and 5-FU for the eradication of cancer
stem cells and differentiated cells would be more effective. As a
result, anti-tumor treatment strategies selectively targeting the
subset of tumor stem cells would be of tremendous clinical
significance for the management of such patients.
In conclusion, in this report, we provide novel evidence and
previously unrecognized effects of curcumin, showing that
curcumin individually or in combination with the conventional
colon cancer chemotherapeutic agent 5-FU could serve as an
effective therapeutic strategy to prevent the emergence of chemo-
resistant colon cancer cells by reducing CSCs. These results are
particularly important from a clinical standpoint, where reduced
toxicity towards the patients is often sought when using these toxic
chemotherapeutic drugs. Our data suggest that a combination
treatment of phytochemicals together with conventional chemo-
therapeutic agents can be very beneficial for the patients in
enhancing the clinical therapy and simultaneously reducing side
effects through lower dosage requirements. Furthermore, MMR-
proficient HCT116+ch3 and their 5-FU resistant counterpart cell
lines are more sensitive to 5-FU and/or curcumin, indicating an
important role for the involvement of DNA MMR-system in
mediating chemosensitization in cancer cells - a topic that is of
burgeoning clinical relevance for the management of CRC
patients that frequently become refractory to conventional
chemotherapy.
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